# A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma

> **NCT04653038** · PHASE1 · TERMINATED · sponsor: **Zai Lab (Shanghai) Co., Ltd.** · enrollment: 92 (actual)

## Conditions studied

- Unresectable, Recurrent or Metastatic Melanoma
- Untreated Mucosal or Acral Lentiginous Melanoma

## Interventions

- **DRUG:** MGD013

## Key facts

- **NCT ID:** NCT04653038
- **Lead sponsor:** Zai Lab (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-29
- **Primary completion:** 2022-03-02
- **Final completion:** 2022-03-02
- **Target enrollment:** 92 (ACTUAL)
- **Why stopped:** rapid changes in the treatment mode of melanoma worldwide and in China and the development strategy change
- **Last updated:** 2024-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04653038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04653038, "A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04653038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*